Peter Andersen, SVP of infectious disease at the Novo Nordisk Foundation
December 18, 2023 08:28 AM ESTUpdated December 19, 07:00 AM
R&D
Manufacturing

No­vo Nordisk Foun­da­tion to launch $260M vac­cine ini­tia­tive in ear­ly 2024

Anna Brown

News Reporter

The No­vo Nordisk Foun­da­tion, which op­er­ates in­de­pen­dent­ly from the phar­ma com­pa­ny, is pump­ing DKK 1.8 bil­lion ($260 mil­lion) to launch an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times